EIDXGBP does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2021-09-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
No Form 8-K filings for this ticker
CUSIP
28249H104
FAQ
Who are the top institutional investors holding EIDOS THERAPEUTICS INC (EIDXGBP)?
Major stakeholders currently include BNP Paribas Financial Markets ($130.0K). Based on the latest 13F filings, there are a total of 1 tracked investment funds and institutions maintaining positions in EIDXGBP.
What is the overall institutional sentiment toward EIDXGBP recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $130.0K, driven by 1 managers accumulating shares while 0 reduced their exposure.
Which institutions have been selling or reducing their EIDXGBP positions?
In the latest period, no tracked funds trimmed or exited their positions in EIDXGBP.
Are there any notable investors adding EIDXGBP to their portfolios?
Yes, buying activity remains notable. 1 institutions opened new positions in {ticker}, and 0 existing holders added to their shares. The total reported buy value for the quarter amounted to $130.0K.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter